Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky

INTRODUCTION: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide. METHODS: We conducted a re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunos, Charles A., Fabian, Denise, Piecoro, Dava W., Napier, Dana, Miller, Rachel W., Ueland, Frederick R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902924/
https://www.ncbi.nlm.nih.gov/pubmed/36761943
http://dx.doi.org/10.3389/fonc.2023.948348
_version_ 1784883364553031680
author Kunos, Charles A.
Fabian, Denise
Piecoro, Dava W.
Napier, Dana
Miller, Rachel W.
Ueland, Frederick R.
author_facet Kunos, Charles A.
Fabian, Denise
Piecoro, Dava W.
Napier, Dana
Miller, Rachel W.
Ueland, Frederick R.
author_sort Kunos, Charles A.
collection PubMed
description INTRODUCTION: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide. METHODS: We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial. RESULTS: Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so. DISCUSSION: Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted.
format Online
Article
Text
id pubmed-9902924
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99029242023-02-08 Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky Kunos, Charles A. Fabian, Denise Piecoro, Dava W. Napier, Dana Miller, Rachel W. Ueland, Frederick R. Front Oncol Oncology INTRODUCTION: High-risk human epidermal growth factor receptor 2 (HER2)-positive adenocarcinomas associate with early recurrence and death, prompting consideration of novel radiotherapeutic options like a trastuzumab-linked thorium-227 alpha-particle emitting radionuclide. METHODS: We conducted a retrospective pilot biomarker study of uterine cervix cancers among patients in Appalachian Kentucky, to characterize an exploitable triage biomarker like HER2 expression before starting a prospective phase 0 trial. RESULTS: Most (60%) adenocarcinomas showed HER2 cell-surface overexpression, whereas squamous cell carcinomas (4%) did not do so. DISCUSSION: Further validation tests of HER2 expression as a triage biomarker for radiopharmaceutical selection are warranted. Frontiers Media S.A. 2023-01-24 /pmc/articles/PMC9902924/ /pubmed/36761943 http://dx.doi.org/10.3389/fonc.2023.948348 Text en Copyright © 2023 Kunos, Fabian, Piecoro, Napier, Miller and Ueland https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kunos, Charles A.
Fabian, Denise
Piecoro, Dava W.
Napier, Dana
Miller, Rachel W.
Ueland, Frederick R.
Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky
title Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky
title_full Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky
title_fullStr Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky
title_full_unstemmed Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky
title_short Human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from Appalachian Kentucky
title_sort human epidermal growth factor receptor 2 expression in women with uterine cervix adenocarcinoma from appalachian kentucky
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902924/
https://www.ncbi.nlm.nih.gov/pubmed/36761943
http://dx.doi.org/10.3389/fonc.2023.948348
work_keys_str_mv AT kunoscharlesa humanepidermalgrowthfactorreceptor2expressioninwomenwithuterinecervixadenocarcinomafromappalachiankentucky
AT fabiandenise humanepidermalgrowthfactorreceptor2expressioninwomenwithuterinecervixadenocarcinomafromappalachiankentucky
AT piecorodavaw humanepidermalgrowthfactorreceptor2expressioninwomenwithuterinecervixadenocarcinomafromappalachiankentucky
AT napierdana humanepidermalgrowthfactorreceptor2expressioninwomenwithuterinecervixadenocarcinomafromappalachiankentucky
AT millerrachelw humanepidermalgrowthfactorreceptor2expressioninwomenwithuterinecervixadenocarcinomafromappalachiankentucky
AT uelandfrederickr humanepidermalgrowthfactorreceptor2expressioninwomenwithuterinecervixadenocarcinomafromappalachiankentucky

Ejemplares similares